ClinicalTrials.gg
CompletedNCT01511536Updated Jul 28, 2016Results posted

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

A Phase 1/2 interventional study of Cabazitaxel XRP6258 and Abiraterone acetate in Prostate Cancer, sponsored by Sanofi. Completed at 4 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-28.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
62nd of 98
38 · median 56
Started
2012
with 6 others
Phase 1/2
8 of 98
none open now
Registered
19th of 98
by date

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 62nd largest by enrollment, is one of 7 that started in 2012, is one of 8 in phase 1/2, and was the 19th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objectives:

  • To determine the maximum tolerated dose, and dose limiting toxicities of cabazitaxel administered as a 1-hour infusion every 3 weeks in combination with oral daily abiraterone acetate and prednisone in participants with metastatic Castrate-resistant prostate cancer (CRPC)
  • To estimate the anti-tumor activity of cabazitaxel in combination with abiraterone acetate and prednisone in terms of prostate-specific antigen (PSA) response rate.

Secondary Objectives:

  • To characterize the safety profile of the combination
  • To evaluate the pharmacokinetic profile of cabazitaxel and abiraterone in the proposed combination and dosing schedule
  • To assess preliminary antitumor activity of the combination in terms of progression-free survival, PSA progression free survival and objective response rate, and overall survival
Read the detailed description

The study duration was to include a period for inclusion of up to 3 weeks and a 3-week treatment cycle(s). The participants might continue treatment until disease progression, unacceptable toxicity or willingness to stop followed by a minimum of 30-day follow-up

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of prostate adenocarcinoma proven histologically or cytologically, resistant to hormone therapy and previously treated with a docetaxel-containing regimen. In Phase 2 part, participants should have been treated with abiraterone acetate for at least 3 months and should continue treatment with abiraterone acetate before study entry
  • Presence of prostate cancer.
  • Participant must had progressive disease documented by rising PSA defined as 2 sequential increases above a previous lowest reference value (each PSA value must be obtained at least 1 week apart. A PSA value of at least 6 ng/mL was required at study entry). In Phase 1 part, in addition to rising PSA, progressive disease must be documented by:

    1. Increase in non-measureable or , and/or
    2. Appearance of new lesions, including those on bone scan (≥2 new lesions on 2 consecutive bone scans if progressive disease diagnosed on bone scan only) consistent with progressive prostate cancer
  • Effective castration (serum testosterone levels ≤0.50 ng/mL) by orchiectomy and/or luteinizing hormone-releasing hormone agonists /antagonist.

    1. If the participant had been treated with luteinizing hormone-releasing hormone agonists/antagonist (i.e., without orchiectomy), then this therapy had been initiated at least 4 weeks prior to cycle 1 day 1 and should be continued throughout the study.
    2. Prior anti-androgen therapy should be stopped before enrollment
  • performance status: 0 - 1.

Exclusion criteria

Exclusion criteria:

Previous treatment with mitoxantrone or cabazitaxel.

  • Prior bone-seeking radio-isotope therapy (participants treated with Radium223 were not excluded from the study). Radiotherapy to ≥30% of bone marrow.
  • Adverse events from any prior anticancer therapy of grade >1 at the time of enrollment.

Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study (except luteinizing hormone-releasing hormone agonist /antagonist and abiraterone acetate in the Phase 2 part of the study); small field single fraction palliative radiation within 1 week.

  • Prior . Curatively treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which chemotherapy had been completed ≥ 3 years ago and from which the participant had been disease-free for ≥ 3 years.
  • Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to enrollment.
  • Known brain or .
  • Any severe acute or chronic medical condition which could impair the ability of the participant to participate to the study or to comply with the study procedures or interfere with interpretation of study results.
  • Other concurrent serious illness or medical conditions
  • Absence of signed and dated participant form prior to enrollment into the study.
  • History of to docetaxel, polysorbate 80
  • Known allergies, hypersensitivity or intolerance to prednisone or of abiraterone acetate
  • Known history of mineralocorticoid excess or deficiency
  • Inadequate organ and bone marrow function
  • to the use of treatment.
  • Symptomatic peripheral neuropathy grade > 1
  • Concurrent treatment with strong inducers or strong inhibitors of cytochrome P450 (CYP450) 3A4
  • Concurrent treatment with medications metabolized by cytochrome P2D6 (CYP2D6), particularly for those with a small therapeutic window
  • History of cardiac arrhythmias requiring medical therapy such as atrial fibrillation requiring anticoagulation or digoxin/digitalis; uncontrolled angina pectoris. History of congestive heart failure or myocardial infarction within last 6 months was also not allowed.
  • Uncontrolled hypertension (systolic BP ≥160 mmHg or diastolic BP ≥ 95 mmHg). Participants with a history of hypertension were allowed, provided that blood pressure was controlled to within these limits by anti-hypertensive treatment
  • heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 12 months, severe or unstable angina, or Class III or IV heart disease or cardiac measurement of \<50% at baseline
  • Participants with who did not agree to use accepted and effective method of in conjunction with their partner(s) during the study treatment period.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg

    Cabazitaxel 20 mg/m\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.

    Drug: Cabazitaxel XRP6258 · Drug: Abiraterone acetate · Drug: Prednisone 5 mg

  • Experimental
    Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg

    Cabazitaxel 25 mg/m\^2 IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.

    Drug: Cabazitaxel XRP6258 · Drug: Abiraterone acetate · Drug: Prednisone 5 mg

  • Experimental
    Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg

    Cabazitaxel at maximum tolerated dose (MTD) as determined in phase 1 part (25 mg/m\^2) IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.

    Drug: Cabazitaxel XRP6258 · Drug: Abiraterone acetate · Drug: Prednisone 5 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate

    MTD was defined as highest dose level of cabazitaxel in combination with abiraterone acetate at which no more than 1 participant experienced dose limiting toxicities (DLT). DLT was defined as any of the following events related to study treatment: 1) Grade 3 or 4 non-hematological related adverse event with exception of Grade 3 fever without documented infection; Grade 3 nausea, vomiting, or diarrhea in the absence of effective maximal therapy; and Grade 3 hypersensitivity reaction in the absence of required premedication. 2) Hematological toxicity: Febrile neutropenia (fever of unknown origin ≥38.5°C with neutropenia Grade 3 or 4); Neutropenia Grade 4 lasting \>7 days; Thrombocytopenia Grade 4 or Grade 3 complicated by hemorrhage. 3) Re-treatment delay of more than 2 weeks due to delayed recovery from a toxicity related to study treatment to baseline or ≤ Grade 1 (except for alopecia). Grades were based on National Cancer Institute CommonTerminology Criteria for Adverse Events v4.03.

    Time frame: Up to Cycle 2 of Phase 1 (up to 42 days)

  2. Phase 2: Percentage of Participants With Prostate Specific Antigen (PSA) Response

    Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response. PSA was to be measured at baseline, every 3 weeks, throughout study period, until progression. PSA progression was defined as: -An increase of 25% above the nadir (at least 2 ng/mL), confirmed by a second PSA value at least 3 weeks apart, in participants who have achieved a ≥50% decline of PSA. -An increase in PSA by 25 % above the baseline level (at least 2 ng/mL), confirmed by a second PSA value at least 3 weeks apart, in participants who have not achieved a ≥50% decline of PSA.

    Time frame: Baseline, every 3 weeks up to PSA progression (maximum duration: 603 days)

Secondary outcomes

  1. Phase 2: Objective Progression Free Survival (PFS)

    Objective PFS was defined as the time interval between the date of enrollment and the first occurrence of any of the events: 1) Radiological tumor progression (assessed using Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. in case of progressive disease (PD) diagnosed only on non target bone lesions on bone scan, PD was to be considered only in case of appearance of at least 2 new lesions on bone scan confirmed 6 weeks later by another bone scan, and at least the appearance of 2 new additional lesions. 2) Death due to any cause. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline until radiological tumor or disease progression or death due to any cause, assessed up to Month 5

  2. Phase 2: PSA Progression Free Survival

    Prostate-specific antigen progression-free survival was defined as the time interval between the date of treatment start and the date of either first documented PSA progression or death due to any cause, whichever was earlier. PSA was to be measured at baseline, every 3 weeks, throughout study period, until progression. PSA progression was defined as: -An increase of 25% above the nadir (at least 2 ng/mL), confirmed by a second PSA value at least 3 weeks apart, in participants who have achieved a ≥50% decline of PSA. -An increase in PSA by 25 % above the baseline level (at least 2 ng/mL), confirmed by a second PSA value at least 3 weeks apart, in participants who have not achieved a ≥50% decline of PSA. Analysis was performed by Kaplan Meire method.

    Time frame: Baseline, every 3 weeks up to PSA progression (maximum duration: 603 days)

  3. Phase 2: Percentage of Participants With Objective Response

    Objective response was defined as having complete response (CR) or Partial Response (PR) assessed by RECIST 1.1. CR was defined as disappearance of all target, non-target lesions; normalization of tumor marker level and all lymph nodes size was \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters).

    Time frame: Baseline, every 12 weeks there after until disease progression (maximum duration: 603 days)

  4. Phase 2: Overall Survival

    Overall survival was defined as the time interval from the date of treatment start to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earlier of the last date the participant was known to be alive and the study cut-off date. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline up to death or study cut-off (maximum duration: 603 days)

  5. Phase 2: Pharmacokinetic of Cabazitaxel : Maximum Plasma Concentration Observed (Cmax)

    Time frame: 5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1

  6. Phase 2: Pharmacokinetic of Cabazitaxel : Area Under the Plasma Concentration Versus Time Curve (AUC)

    Area under the concentration-time curve calculated using the following equation: AUC = Plasma clearance (CL)/dose

    Time frame: 5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1

  7. Phase 2: Pharmacokinetic of Cabazitaxel : Terminal Half-life (t 1/2z)

    Time frame: 5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1

  8. Phase 2: Pharmacokinetic of Cabazitaxel : Total Plasma Clearance (CL)

    Time frame: 5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1

  9. Phase 2: Pharmacokinetic of Cabazitaxel : Volume of Distribution at Steady State (Vss)

    Time frame: 5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1

  10. Phase 2: Pharmacokinetic of Abiraterone : Maximum Plasma Concentration Observed (Cmax)

    Time frame: 0 hour (before abiraterone administration); 1, 2, 4, 6, 8, 12, 24 hours post abiraterone administration on Day 1-Cycle 1

  11. Phase 2: Pharmacokinetic of Abiraterone : First Time to Reach Cmax (Tmax)

    Time frame: 0 hour (before abiraterone administration); 1, 2, 4, 6, 8, 12, 24 hours post abiraterone administration on Day 1-Cycle 1

  12. Phase 2: Pharmacokinetic of Abiraterone : Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC 0-24)

    Area under the plasma concentration-time curve calculated using the trapezoidal method from time zero to 24 hours corresponding to abiraterone acetate dosing interval.

    Time frame: 0 hour (before abiraterone administration); 1, 2, 4, 6, 8, 12, 24 hours post abiraterone administration on Day 1-Cycle 1

  13. Phase 2: Pharmacokinetic of Abiraterone : Concentration Observed Just Before Treatment Administration During Repeated Dosing at Steady State (Ctrough ss)

    Time frame: Pre abiraterone dose on Day 1 of Cycle 1

07

Results

Posted Nov 4, 2015

Participant flow

Participants were enrolled at 2 centers in phase 1 part and 3 centers in phase 2 part between March 2012 and April 2014.

Phase 1
Participant flow — Phase 1
MilestonePhase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mgPhase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mgPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Started370
Completed360
Not completed010
Withdrew: Other010
Phase 2
Participant flow — Phase 2
MilestonePhase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mgPhase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mgPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Started0027
Completed0018
Not completed009
Withdrew: Other009

Outcome measures

PrimaryPhase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate

MTD was defined as highest dose level of cabazitaxel in combination with abiraterone acetate at which no more than 1 participant experienced dose limiting toxicities (DLT). DLT was defined as any of the following events related to study treatment: 1) Grade 3 or 4 non-hematological related adverse event with exception of Grade 3 fever without documented infection; Grade 3 nausea, vomiting, or diarrhea in the absence of effective maximal therapy; and Grade 3 hypersensitivity reaction in the absence of required premedication. 2) Hematological toxicity: Febrile neutropenia (fever of unknown origin ≥38.5°C with neutropenia Grade 3 or 4); Neutropenia Grade 4 lasting \>7 days; Thrombocytopenia Grade 4 or Grade 3 complicated by hemorrhage. 3) Re-treatment delay of more than 2 weeks due to delayed recovery from a toxicity related to study treatment to baseline or ≤ Grade 1 (except for alopecia). Grades were based on National Cancer Institute CommonTerminology Criteria for Adverse Events v4.03.

Time frame:
Up to Cycle 2 of Phase 1 (up to 42 days)
Reported as:
Number · mg/m^2
Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate
mg/m^2Phase 1: Overall Population
Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate25
PrimaryPhase 2: Percentage of Participants With Prostate Specific Antigen (PSA) Response

Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response. PSA was to be measured at baseline, every 3 weeks, throughout study period, until progression. PSA progression was defined as: -An increase of 25% above the nadir (at least 2 ng/mL), confirmed by a second PSA value at least 3 weeks apart, in participants who have achieved a ≥50% decline of PSA. -An increase in PSA by 25 % above the baseline level (at least 2 ng/mL), confirmed by a second PSA value at least 3 weeks apart, in participants who have not achieved a ≥50% decline of PSA.

Time frame:
Baseline, every 3 weeks up to PSA progression (maximum duration: 603 days)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Prostate Specific Antigen (PSA) Response
percentage of participantsPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Phase 2: Percentage of Participants With Prostate Specific Antigen (PSA) Response46.2 (26.6 to 66.6)
SecondaryPhase 2: Objective Progression Free Survival (PFS)

Objective PFS was defined as the time interval between the date of enrollment and the first occurrence of any of the events: 1) Radiological tumor progression (assessed using Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. in case of progressive disease (PD) diagnosed only on non target bone lesions on bone scan, PD was to be considered only in case of appearance of at least 2 new lesions on bone scan confirmed 6 weeks later by another bone scan, and at least the appearance of 2 new additional lesions. 2) Death due to any cause. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline until radiological tumor or disease progression or death due to any cause, assessed up to Month 5
Reported as:
Median · months
Phase 2: Objective Progression Free Survival (PFS)
monthsPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Phase 2: Objective Progression Free Survival (PFS)NA (4.731 to NA)
SecondaryPhase 2: PSA Progression Free Survival

Prostate-specific antigen progression-free survival was defined as the time interval between the date of treatment start and the date of either first documented PSA progression or death due to any cause, whichever was earlier. PSA was to be measured at baseline, every 3 weeks, throughout study period, until progression. PSA progression was defined as: -An increase of 25% above the nadir (at least 2 ng/mL), confirmed by a second PSA value at least 3 weeks apart, in participants who have achieved a ≥50% decline of PSA. -An increase in PSA by 25 % above the baseline level (at least 2 ng/mL), confirmed by a second PSA value at least 3 weeks apart, in participants who have not achieved a ≥50% decline of PSA. Analysis was performed by Kaplan Meire method.

Time frame:
Baseline, every 3 weeks up to PSA progression (maximum duration: 603 days)
Reported as:
Median · months
Phase 2: PSA Progression Free Survival
monthsPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Phase 2: PSA Progression Free Survival6.93 (4.140 to 10.251)
SecondaryPhase 2: Percentage of Participants With Objective Response

Objective response was defined as having complete response (CR) or Partial Response (PR) assessed by RECIST 1.1. CR was defined as disappearance of all target, non-target lesions; normalization of tumor marker level and all lymph nodes size was \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters).

Time frame:
Baseline, every 12 weeks there after until disease progression (maximum duration: 603 days)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Objective Response
percentage of participantsPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Phase 2: Percentage of Participants With Objective Response21.4 (4.7 to 50.8)
SecondaryPhase 2: Overall Survival

Overall survival was defined as the time interval from the date of treatment start to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earlier of the last date the participant was known to be alive and the study cut-off date. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline up to death or study cut-off (maximum duration: 603 days)
Reported as:
Median · months
Phase 2: Overall Survival
monthsPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Phase 2: Overall SurvivalNA (9.429 to NA)
SecondaryPhase 2: Pharmacokinetic of Cabazitaxel : Maximum Plasma Concentration Observed (Cmax)
Time frame:
5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1
Reported as:
Mean · ng/mL
Phase 2: Pharmacokinetic of Cabazitaxel : Maximum Plasma Concentration Observed (Cmax)
ng/mLPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Cabazitaxel : Maximum Plasma Concentration Observed (Cmax)330 ± 187
SecondaryPhase 2: Pharmacokinetic of Cabazitaxel : Area Under the Plasma Concentration Versus Time Curve (AUC)

Area under the concentration-time curve calculated using the following equation: AUC = Plasma clearance (CL)/dose

Time frame:
5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1
Reported as:
Mean · ng*h/mL
Phase 2: Pharmacokinetic of Cabazitaxel : Area Under the Plasma Concentration Versus Time Curve (AUC)
ng*h/mLPhase 2: Cabazitaxel 25 mg/ m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Cabazitaxel : Area Under the Plasma Concentration Versus Time Curve (AUC)817 ± 117
SecondaryPhase 2: Pharmacokinetic of Cabazitaxel : Terminal Half-life (t 1/2z)
Time frame:
5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1
Reported as:
Mean · hour
Phase 2: Pharmacokinetic of Cabazitaxel : Terminal Half-life (t 1/2z)
hourPhase 2: Cabazitaxel 25 mg/ m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Cabazitaxel : Terminal Half-life (t 1/2z)91.6 ± 62.6
SecondaryPhase 2: Pharmacokinetic of Cabazitaxel : Total Plasma Clearance (CL)
Time frame:
5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1
Reported as:
Mean · L/h/m^2
Phase 2: Pharmacokinetic of Cabazitaxel : Total Plasma Clearance (CL)
L/h/m^2Phase 2: Cabazitaxel 25 mg/ m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Cabazitaxel : Total Plasma Clearance (CL)31.4 ± 4.67
SecondaryPhase 2: Pharmacokinetic of Cabazitaxel : Volume of Distribution at Steady State (Vss)
Time frame:
5 minutes before cabazitaxel infusion; at end of cabazitaxel infusion; 0.25 hours post-cabazitaxel infusion; any time between 1 to 4 hours, between 6 to 24 hours, between 48 to 96 hours post cabazitaxel infusion on Day 1-Cycle 1
Reported as:
Mean · L/m^2
Phase 2: Pharmacokinetic of Cabazitaxel : Volume of Distribution at Steady State (Vss)
L/m^2Phase 2: Cabazitaxel 25 mg/ m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Cabazitaxel : Volume of Distribution at Steady State (Vss)2711 ± 2493
SecondaryPhase 2: Pharmacokinetic of Abiraterone : Maximum Plasma Concentration Observed (Cmax)
Time frame:
0 hour (before abiraterone administration); 1, 2, 4, 6, 8, 12, 24 hours post abiraterone administration on Day 1-Cycle 1
Reported as:
Mean · ng/mL
Phase 2: Pharmacokinetic of Abiraterone : Maximum Plasma Concentration Observed (Cmax)
ng/mLPhase 2: Cabazitaxel 25 mg/ m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Abiraterone : Maximum Plasma Concentration Observed (Cmax)216 ± 152
SecondaryPhase 2: Pharmacokinetic of Abiraterone : First Time to Reach Cmax (Tmax)
Time frame:
0 hour (before abiraterone administration); 1, 2, 4, 6, 8, 12, 24 hours post abiraterone administration on Day 1-Cycle 1
Reported as:
Median · hour
Phase 2: Pharmacokinetic of Abiraterone : First Time to Reach Cmax (Tmax)
hourPhase 2: Cabazitaxel 25 mg/ m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Abiraterone : First Time to Reach Cmax (Tmax)2.00 (1.00 to 6.00)
SecondaryPhase 2: Pharmacokinetic of Abiraterone : Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC 0-24)

Area under the plasma concentration-time curve calculated using the trapezoidal method from time zero to 24 hours corresponding to abiraterone acetate dosing interval.

Time frame:
0 hour (before abiraterone administration); 1, 2, 4, 6, 8, 12, 24 hours post abiraterone administration on Day 1-Cycle 1
Reported as:
Mean · ng*h/mL
Phase 2: Pharmacokinetic of Abiraterone : Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC 0-24)
ng*h/mLPhase 2: Cabazitaxel 25 mg/ m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Abiraterone : Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC 0-24)928 ± 466
SecondaryPhase 2: Pharmacokinetic of Abiraterone : Concentration Observed Just Before Treatment Administration During Repeated Dosing at Steady State (Ctrough ss)
Time frame:
Pre abiraterone dose on Day 1 of Cycle 1
Reported as:
Mean · ng/mL
Phase 2: Pharmacokinetic of Abiraterone : Concentration Observed Just Before Treatment Administration During Repeated Dosing at Steady State (Ctrough ss)
ng/mLPhase 2: Cabazitaxel 25 mg/ m^2 + Abiraterone 1000 mg
Phase 2: Pharmacokinetic of Abiraterone : Concentration Observed Just Before Treatment Administration During Repeated Dosing at Steady State (Ctrough ss)9.99 ± 13.0

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (603 days) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg—3/3 (100%)3/3 (100%)
Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg—4/7 (57.1%)7/7 (100%)
Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg—21/27 (77.8%)27/27 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPhase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mgPhase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mgPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
Small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/70/27
Cardiac failureCardiac disorders1/30/70/27
Myocardial ischaemiaCardiac disorders1/30/70/27
ProstatitisReproductive system and breast disorders1/30/70/27
FatigueGeneral disorders1/31/70/27
Urinary tract infectionInfections and infestations0/30/74/27
HydronephrosisRenal and urinary disorders0/30/74/27
Parasitic gastroenteritisInfections and infestations0/31/70/27
DyspnoeaRespiratory, thoracic and mediastinal disorders0/31/71/27
Abdominal painGastrointestinal disorders0/31/70/27
Most frequent other events
Showing 10 of 85
Most frequent other events
EventPhase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mgPhase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mgPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg
NauseaGastrointestinal disorders1/35/714/27
InsomniaPsychiatric disorders2/30/70/27
Abdominal pain upperGastrointestinal disorders2/31/70/27
ConstipationGastrointestinal disorders2/32/76/27
DiarrhoeaGastrointestinal disorders2/33/715/27
AstheniaGeneral disorders2/33/716/27
PyrexiaGeneral disorders2/30/73/27
Decreased appetiteMetabolism and nutrition disorders1/31/713/27
Weight decreasedInvestigations0/32/713/27
DyspnoeaRespiratory, thoracic and mediastinal disorders0/32/711/27

Baseline characteristics

All treated/safety population defined as all registered participants exposed to both investigational medicinal product (IMP) components, regardless of the amount of treatment administered.

Age, Continuous
Age, Continuous(years)Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mgPhase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mgPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mgTotal
Mean71.0 ± 7.060.0 ± 10.067.1 ± 5.466.1 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mgPhase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mgPhase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mgTotal
Female0000
Male372737
08

Study locations

4 sites
  • Investigational Site Number 840001
    San Francisco, California, United States
  • Investigational Site Number 840002
    New Haven, Connecticut 06510, United States
  • Investigational Site Number 250001
    Villejuif, 94805, France
  • Investigational Site Number 826001
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Massard C, Mateo J, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Ann Oncol. 2017 Jan 1;28(1):90-95. doi: 10.1093/annonc/mdw441. PubMed 28039155 ↗
  • Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 2012 Jul 2;5:35. doi: 10.1186/1756-8722-5-35. PubMed 22747660 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jul 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2012
First posted
Jan 18, 2012
Start
Mar 2012
Primary completionActual
Jul 2014
CompletionActual
Dec 2014
Results first posted
Nov 4, 2015
Last update
Jul 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01511536
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 18, 2012
Start date
Mar 2012
Primary completion
Jul 2014
Completion
Dec 2014
Results posted
Nov 4, 2015
Last update
Jul 28, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate · Prednisone

Start the discussion